TNF Inhibitors May Reduce Cardiovascular Risks in Psoriasis Patients: Report From the AAD Meeting

Dr. Jashin Wu discusses results from a study on tumor necrosis factor (TNF) inhibitors for psoriasis and myocardial infarction risk. The study evaluated TNF inhibitor use, oral therapy and phototherapy, and topical therapy. He also reviews results from another study that looked at heart attacks, stroke, and cardiovascular death with biologics, methotrexate, retinoids, cyclosporine, and other therapies for psoriasis. If we want to believe there is a reduction of cardiovascular risk with TNF inhibitors, what's the mechanism? Dr. Wu presents several theories.